Mar 11, 2025 · Dupixent may be used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic rhinosinusitis with nasal polyps, COPD with an eosinophilic phenotype, eosinophilic esophagitis (EOE), or prurigo nodularis. Dupixent is given as a subcutaneous injection every 1 to 4 weeks. People can be taught how to self-administer it.

Oct 10, 2024 · Dupixent (generic name: dupilumab) is approved to treat certain age groups with eczema (atopic dermatitis), asthma, chronic rhinosinusitis (sinus and nasal cavity swelling) with nasal polyps (tissue growths), chronic obstructive pulmonary disease (COPD), eosinophilic esophagitis, and prurigo nodularis (a skin condition).

Oct 3, 2024 · Easy-to-read patient tips for Dupixent covering how it works, benefits, risks, and best practices.

DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis. for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Sep 27, 2024 · Preparation for Use. Before injection, remove DUPIXENT from the refrigerator and allow DUPIXENT to reach room temperature (45 minutes for the 300 mg/2 mL pre-filled syringe or pre-filled pen, and 30 minutes for the 200 mg/1.14 mL pre-filled syringe or pre-filled pen) without removing the needle cap.

Jan 13, 2025 · Dupilumab (Dupixent) is used to treat eczema, asthma, chronic rhinosinusitis with nasal polyps, COPD with an eosinophilic phenotype, eosinophilic esophagitis, or prurigo nodularis. All these conditions have inflammation in common. Dupilumab is a subcutaneous injection that can be self-administered using a prefilled syringe or pen every 1 to 4 weeks …

Mar 28, 2023 · For healthcare professionals. Applies to dupilumab: subcutaneous solution. General adverse events. The most common adverse reactions were injection site reactions (which included erythema, edema, pruritus, pain, and swelling), conjunctivitis, allergic conjunctivitis, arthralgia, oral herpes, and eosinophilia.

Oct 3, 2024 · Official answer: No, Dupixent (dupilumab) is not an immunosuppressant or a steroid. Dupixent works by targeting a type of protein called...

Oct 3, 2024 · Official answer: Dupixent (dupilumab) is associated with several different eye problems, including conjunctivitis, blepharitis, dry...

Oct 3, 2024 · Although joint pain is not listed in the product information as a side effect of Dupixent (dupilumab), reports of painful joints, tendinitis, and arthritic-like pain associated with Dupixent use are starting to appear.